Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / COM
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
20,648,023
-
Shares change
-
-407,397
-
Total reported value, excl. options
-
$2,499,803,066
-
Value change
-
-$48,280,917
-
Put/Call ratio
-
57%
-
Number of buys
-
90
-
Number of sells
-
-62
-
Price
-
$121.07
Significant Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q2 2017
201 filings reported holding ICPT - INTERCEPT PHARMACEUTICALS IN - COM as of Q2 2017.
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20,648,023 shares
.
Largest 10 shareholders include FMR LLC (3,750,678 shares), AMERIPRISE FINANCIAL INC (2,576,729 shares), Carmignac Gestion (2,035,592 shares), Capital World Investors (1,925,459 shares), VANGUARD GROUP INC (1,328,133 shares), BlackRock Inc. (1,136,015 shares), ORBIMED ADVISORS LLC (856,554 shares), STATE STREET CORP (749,572 shares), CITADEL ADVISORS LLC (582,896 shares), and JPMORGAN CHASE & CO (503,538 shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.